Free Trial

Pliant Therapeutics (PLRX) Competitors

Pliant Therapeutics logo
$1.57 -0.02 (-1.26%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.58 +0.00 (+0.32%)
As of 07/25/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLRX vs. BNTC, GOSS, CMPS, PRTA, ALT, AURA, RNAC, CAPR, AMRN, and INBX

Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Benitec Biopharma (BNTC), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Prothena (PRTA), Altimmune (ALT), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Capricor Therapeutics (CAPR), Amarin (AMRN), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.

Pliant Therapeutics vs. Its Competitors

Benitec Biopharma (NASDAQ:BNTC) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Benitec Biopharma has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

In the previous week, Benitec Biopharma had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Benitec Biopharma and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Benitec Biopharma's score of 0.83 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Benitec Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Pliant Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Benitec Biopharma has higher revenue and earnings than Pliant Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec Biopharma$80K3,668.44-$21.75M-$1.51-7.40
Pliant TherapeuticsN/AN/A-$210.30M-$3.61-0.43

Benitec Biopharma presently has a consensus price target of $26.00, suggesting a potential upside of 132.56%. Pliant Therapeutics has a consensus price target of $13.31, suggesting a potential upside of 747.93%. Given Pliant Therapeutics' higher possible upside, analysts clearly believe Pliant Therapeutics is more favorable than Benitec Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Pliant Therapeutics
0 Sell rating(s)
12 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Benitec Biopharma's return on equity of -38.26% beat Pliant Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Benitec BiopharmaN/A -38.26% -35.71%
Pliant Therapeutics N/A -67.56%-52.54%

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 8.0% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Benitec Biopharma beats Pliant Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLRX vs. The Competition

MetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$96.38M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.00%
P/E Ratio-0.4321.3228.3920.08
Price / SalesN/A280.80430.0899.95
Price / CashN/A42.7636.2258.56
Price / Book0.318.378.675.88
Net Income-$210.30M-$55.19M$3.25B$258.89M
7 Day Performance9.79%5.86%4.30%3.70%
1 Month Performance20.77%17.29%10.57%11.71%
1 Year Performance-88.26%4.39%35.68%17.98%

Pliant Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLRX
Pliant Therapeutics
4.3405 of 5 stars
$1.57
-1.3%
$13.31
+747.9%
-88.2%$96.38MN/A-0.4390News Coverage
BNTC
Benitec Biopharma
1.7592 of 5 stars
$13.25
+3.7%
$23.83
+79.9%
+22.5%$347.81M$80K-8.7720
GOSS
Gossamer Bio
4.0047 of 5 stars
$1.53
+12.5%
$8.25
+439.2%
+68.8%$347.77M$114.70M-6.65180Gap Up
High Trading Volume
CMPS
COMPASS Pathways
1.7339 of 5 stars
$3.71
+1.1%
$17.00
+358.2%
-42.0%$347.11MN/A-1.86120Upcoming Earnings
PRTA
Prothena
3.736 of 5 stars
$6.43
+0.5%
$31.50
+389.9%
-73.1%$346.11M$137.94M-3.09130
ALT
Altimmune
2.102 of 5 stars
$4.26
+2.9%
$18.20
+327.2%
-39.0%$345.53M$20K-3.3850
AURA
Aura Biosciences
2.6553 of 5 stars
$6.75
+5.5%
$22.00
+225.9%
-29.6%$339.32MN/A-3.5550News Coverage
RNAC
Cartesian Therapeutics
2.2984 of 5 stars
$13.06
-2.0%
$40.00
+206.3%
-19.6%$338.91M$38.91M-0.2564News Coverage
Positive News
Gap Up
CAPR
Capricor Therapeutics
2.7297 of 5 stars
$7.39
-3.3%
$22.56
+205.2%
+59.4%$337.58M$22.27M-5.20101Trending News
Gap Up
AMRN
Amarin
0.2403 of 5 stars
$16.10
-4.9%
$12.00
-25.5%
-2.7%$333.43M$228.61M-4.42360Upcoming Earnings
INBX
Inhibrx Biosciences
3.1485 of 5 stars
$22.96
+5.5%
N/A+71.9%$332.46M$200K0.20166Positive News

Related Companies and Tools


This page (NASDAQ:PLRX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners